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Abstract
We present a 61 year old Para 4 woman who presented with stage II Infiltrating lobular carcinoma
of the breast after modified radical mastectomy. She was treated with Tamoxifen for seven years.
She was diagnosed with multiple myeloma during year seven post mastectomy because of wrist
pain. She was treated with melphalan, prednisone and allopurinol which she tolerated well and the
pain in the wrist improved. Tamoxifen was also stopped. Ten months later she presented with
vaginal bleeding and was diagnosed with a poorly differentiated endometrial adenocarcinoma at
hysteroscopic suction curettage and had an abdominal hysterectomy. Two years later the patient
succumbed to metastatic endometrial cancer.
Background
The development of a second primary cancer after treat-
ment of the first with radiotherapy or chemotherapy is
well documented [1]. This is often seen with hematologi-
cal malignancies in childhood where other malignancies,
usually haematologic follow, when there is good five year
survival [1].
There are several other reasons for a patient to develop
multiple primary malignancies. There may be a genetic
predisposition resulting in the cancer family syndrome.
The BRCA gene mutation would be one such example.
They may also arise as a result of oncogenic viruses such
as HPV and HTLV1. DNA damaging toxins are another
cause for the development of these malignancies. Expo-
sure to carcinogens can affect different organs at the same
time, for example smoking can affect the lungs, nasophar-
ynx and bladder while HPV affects the vulva, vagina and
cervix. In some cases they are related to decreased tumour
suppression in immunocompromised patients. They may
also arise by chance as successful treatment of one malig-
nancy causes prolongation of survival with the possibility
of a second one occurring. We present a case of a woman
who presented with three primary malignancies over a
seven year period.
Case presentation
MW a 61 year old Para 4 presented in 1994, with a history
of a lump in the breast for 5 years. She had noted an
increase in size just prior to presentation. There was no
associated nipple discharge, or pain and she gave no fam-
ily history of breast cancer. In her past history she had
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maleate and had had surgical treatments for a tubal
ectopic gestation and also for carpal tunnel syndrome. On
general examination she was a middle aged woman in
good health. There were no abnormal findings in her res-
piratory, cardiovascular, neurological or musculoskeletal
systems. No masses were palpable in her abdomen and
pelvic examination was normal. The left breast contained
a 3 cm diameter firm mobile lump in the axillary tail
which was not attached to the skin or the chest wall. The
right breast was normal. Both fine needle aspiration and
trucut biopsies of the lump proved to be inadequate for
diagnosis but during the procedures it was noted that the
lump was partially fixed, suggesting malignancy. Excision
biopsy of the lesion proved on histology to be an infiltrat-
ing lobular carcinoma of the breast (figure 1). The patient
elected to have a modified radical mastectomy. This spec-
imen contained six (6) lymph nodes from the axillary dis-
section, all of which were free of metastasis. The deep
resection margin was also free of tumour and she was des-
ignated stage II disease. No radiotherapy was given and
although estrogen receptor studies were unavailable at
that time, she was started on Tamoxifen.
Five years later (1999) she presented with back pain. Radi-
ographs of the spine revealed sclerosis in the body of the
fifth lumbar vertebra. It was thought that this was possibly
metastatic disease but a bone scan was reported as nor-
mal. Mammograms done every year on the remaining
breast were also described as normal. A year later (2000),
about 6 years post-mastectomy, there was no evidence of
recurrence but she was continued on Tamoxifen. In Febru-
ary 2001, seven years after her initial presentation she pre-
sented with pain in the volar aspect of her right wrist for
2–3 months with restriction of movement. She was seen
by the orthopaedic surgeons who found mild swelling
with pain on radial deviation but no pain on compres-
sion, no anteroposterior laxity and no wasting. Radiogra-
phy of the wrist showed a lucent area in distal ulna. This
was confirmed by nuclear bone scan showing a "hot area"
corresponding to the area of lucency. Again this was
thought to be metastatic given the increase in radioiso-
tope uptake which is not usual for the lytic bone disease
in myeloma. Computerised Tomography scan showed a
lesion extending into ulnar styloid process but no cortical
destruction. Haematological and blood biochemical tests
revealed a haemoglobin of 10 g/dl, white blood cell count
of 4.0 × 109/l, platelet count of 164 × 109/l. Her serum
globulins were elevated at 68 g/l, calcium was not elevated
and the erythrocyte sedimentation rate was elevated at 52
mm/hr. Serum Protein electrophoresis revealed a mono-
clonal band in γ region with decreased normal immu-
noglobulins. Bone marrow examination revealed 60 %
plasma cells (figure 2). Multiple Myeloma was diagnosed
based on the presence of >30% plasma cells in the bone
marrow, the monoclonal band and the lytic skeletal
lesion. She was treated with melphalan, prednisone and
allopurinol which she tolerated well and the pain in the
wrist improved. She was advised then by the haematolo-
gists to discontinue tamoxifen as she had already had 5
years of treatment.
In December 2001, ten months after stopping the
tamoxifen, she was again seen because of an episode of
vaginal bleeding which lasted 3 days. The bleeding had
been moderate and unprovoked. The history of breast
cancer and prolonged tamoxifen use were noted. She had
no family history of cancer or of being immunocompro-
mised. and no history of exposure to industrial toxins.
Gynaecological examination was normal except for her
uterus of 14 weeks size attributed to uterine fibroids. The
cervix appeared normal and a cervical smear was reported
as normal. Hysteroscopy was performed which showed a
fundal lesion which was removed by suction curettage.
The pathology report was that of a poorly differentiated
adenocarcinoma (figure 3). She was thus counseled and
consented to have a total abdominal hysterectomy. Preop-
erative investigation revealed Haematological and blood
biochemical tests revealed a haemoglobin of 9.6 g/dl,
white blood cell count of 5.7 × 109/l, platelet count of 174
× 109/l. Her serum globulins were elevated at 53 g/l, cal-
cium was not elevated, normal blood sugar, normal liver
function, normal renal function and a normal chest radi-
ograph. Her serology for HIV and HTLV1 were both non
reactive. She had a total abdominal hysterectomy with
bilateral salpingo-oophorectomy. The histology from this
procedure was similar to that obtained at suction curet-
tage. Staging from the surgery and histology placed her in
the category of 1b disease. Unfortunately she died two
years later from metastatic disease from this malignancy.
Conclusion
The main risk factor in this patient appears to have been
the long term use of the drug tamoxifen. This is a selective
estrogen receptor modulator and a known risk of
endometrial cancer and sarcomas [2-4]. Tamoxifen is use-
ful as adjuvant treatment of surgically excised breast can-
cer. It is usually reserved for oestrogen receptor positive
breast cancer patients. With its use, recurrence is decreased
by 50%, mortality decreased by 28% [5] and there is a
lower incidence of contralateral breast cancer. In one pla-
cebo, double blind randomised trial; there was a 49%
reduction in breast cancer in high risk women [6]. How-
ever since it is not without complication, patients should
be informed of the risks which include venous throm-
boembolism, cataracts and endometrial cancer. The cur-
rent standard recommendation for use of tamoxifen as
adjuvant treatment for breast cancer is 5 years. Use for
longer than five years has not been shown to give anyPage 2 of 5
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Figure 1
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[7]. Long term users of tamoxifen also appear to over
express the p53 protein on immunohistochemical analy-
sis and this protein is strongly associated with sarcomas
and poorly differentiated endometrial carcinomas of the
endometrium as was found in this patient who had taken
tamoxifen for about seven years [7]. Risk ratio for
endometrial cancer is about two and a half to seven times
normal in patients being treated with tamoxifen [7]. Non
invasive screening procedures such as ultrasonographic
endometrial thickness measurement may be beneficial as
it has been shown that an endometrial thickness of less
than 5 mm is not usually associated with endometrial
cancer [8]. However while this has been studied in
women with postmenopausal bleeding less is known
about it in women on tamoxifen.
The occurrence of the multiple myeloma (MM) appears to
have been just a chance event. In this case breast cancer is
the most common cancer in Jamaican women Age stand-
ardized rate (ASR) 43.2/100,000 (incidence at age 60
173.1/100,000) [9] and multiple myeloma is common in
this age group with a reported incidence of 29.3/100,000
at age 60 years (ASR 3.4/100,000) [9]. Endometrial cancer
is also common in this age group reported incidence 50.6/
100,000 (ASR 9.8/100,000) [9]. Successful treatment of
one cancer will result in the patient living long enough for
another age related cancer to arise by chance. This phe-
nomenon has been alluded to in a report from Martinique
of adult T cell lymphoma occurring by chance with MM,
because in that country HTLV1 (associated with ATL) is
endemic and MM is common [10].
The occurrence of a bone lesion was at first thought to be
a metastatic lesion from the breast however her other
studies done confirmed MM which required a different
treatment which was successful. A second malignancy
should be suspected if the bone lesion is atypical or if the
blood studies are not in keeping with breast cancer.
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The occurrence of the other problems found in this
patient may also be linked to her predisposition to malig-
nancy. Oxidative DNA damage is significantly increased
in the trabecular meshwork of glaucoma patients. One
study found that Genotypes of glutathione S-transferase
isoenzymes were significantly higher in glaucoma patients
than in controls. Genotypes of glutathione S-transferase
iso-enzyme GSTM1 gene deletion, has been associated
with an increased risk of cancer at various sites [11].
Unfortunately the genotype of this patient is unknown.
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